Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 26 for pancreatic cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  3. A Study to Evaluate Hyperthermic Intraperitoneal Chemotherapy to Treat Patients with Pancreatic Cancer and Peritoneal Metastasis

    Rochester, MN

  4. Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) in Patients with Metastatic Pancreatic Adenocarcinoma

    Jacksonville, FL

  5. Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  6. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

    Rochester, MN

  7. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

    Rochester, MN, Scottsdale/Phoenix, AZ, Rochester, MN

  8. Oligomets pancreas SBRT

    Jacksonville, FL

  9. A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer